Figure 5. Niche derived Wnt4 signals via RhoA to promote quiescence.

(A) Quantification of active Rho expression in Control and SC-RhoA^fl/+FACS isolated SCs, 14d post tmx (n=3).

(B) Quantification of pMLC expression in SCs on Control and SC-RhoA^fl/+ isolated single muscle fibers, 14d post tmx (n=3).

(C) Quantification of Pax7⁺ cells per 1mm² TA muscle section of Control and SC-RhoA^fl/+, 14d post tmx (n=3).

(D) Percentage of BrdU⁺ SCs in Control and SC-RhoA^fl/+ TA muscle sections, 14d post tmx (n=3).

(E) MyoD expression in SCs on isolated muscle fibers treated with PBS, Rhol inhibitor or ROCK inhibitor for 8h in vitro (n=2).

(F) MyoD expression in SCs on muscle fibers from Control and Myofiber-Wnt4^fl/fl treated with Rho activator for 8h in vitro (n=3).

(G) pMLC expression in SCs on muscle fibers from Control and Myofiber-Wnt4^fl/fl treated with Rho activator for 2h in vitro (n=3).

(H and I) Representative images (H) and quantification (I) of the percent pS6⁺ SCs on Control and Myofiber-Wnt4^fl/fl muscle fibers, 14d post tmx (n=4).

(J) Percentage of pS6⁺ SCs on Control and SC-RhoA^fl/+ muscle fibers, 14d post tmx (n=3).

The dashed line in Figures 5E, 5F and 5G represents the threshold of intensity visible by eye.

Error bars, s.e.m.; *P<0.05, **P<0.01, ****P<0.0001; Scale bars 5μm in (H).